Compare Enveric Biosciences Inc (ENVB) vs Las Vegas Sands Corp. (LVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Las Vegas Sands Corp. — how do they compare? Enveric Biosciences Inc trades at $1.45 (market cap $6.20M), while Las Vegas Sands Corp. trades at $45.83 (market cap $29.44B). The key difference: Las Vegas Sands Corp. is far larger — about 4748.4× Enveric Biosciences Inc's market cap, and Las Vegas Sands Corp. pays a 2.64% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | LVS | |
|---|---|---|
Market Cap | $6.20M | $29.44B |
Sector | Health | Consumer Cyclical |
52-Week High | $17.40 | $69.49 |
52-Week Low | $1.27 | $44.78 |
Enterprise Value | $1.30M | $41.33B |
Dividend Yield | — | 2.64% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →
